Novartis India
NOVARTIND · Retail > Trading · Chairman: C Snook · MD: Sanjay Murdeshwar · Listing date: Nov. 9, 2000 · Employees: 539 · Mumbai · http://www.novartis.in

Stock Price vs Company Growth
1d
2.3%
1w
0.9%
1m
6.7%
3m
19.0%
6m
5.0%
1y
15.6%
5y
14.0%
all
8.5%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 937 2.3%
750
1,074
Company Overview

Sales
348 Cr
Growth: 0.6%
Profit after Tax
97.2 Cr
Growth: -8.8%
Small Cap
2,314 Cr
P/E: 23.8x
Industry P/E: 19.8x
Fundamentals

Sales (Cr) ₹ 348
Growth 0.6%
EBITDA 28.0%
P/S 6.7x
Dividend 2.1%
P/E 23.8x
Book Value ₹ 345
PEG Ratio 38.7x
ROE 11.8%
P/B 2.7x
Shareholding Pattern

Institutions
Promoters
Novartis Ag
70.68 %
Others
Atul Limited
1.52 %
Iepf
0.47 %
Llp, Partnership Firm, Directors' Relative
0.14 %
Increase    Decrease    No change
Company Profile Detailed

As a science-based and patient-oriented healthcare company, it strives to be a global leader in growing areas of healthcare. Following a corporate transformation Novartis globally is focused on three divisions with global scale and innovation power - pharmaceuticals, eye care and generic medicines. This has strengthened the future growth prospects of the company.
Investors (7)
Followers (1)